What is the official website of MSD Portugal ?

The official website of MSD Portugal is http://msd.pt/.

What is MSD Portugal's cybersecurity risk score?

MSD Portugal has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has MSD Portugal experienced?

According to Rankiteo, MSD Portugal currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has MSD Portugal been affected by any supply chain cyber incidents ?

According to Rankiteo, MSD Portugal has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does MSD Portugal have SOC 2 Type 1 certification ?

According to Rankiteo, MSD Portugal is not certified under SOC 2 Type 1.

Does MSD Portugal have SOC 2 Type 2 certification ?

According to Rankiteo, MSD Portugal does not hold a SOC 2 Type 2 certification.

Does MSD Portugal comply with GDPR ?

According to Rankiteo, MSD Portugal is not listed as GDPR compliant.

Does MSD Portugal have PCI DSS certification ?

According to Rankiteo, MSD Portugal does not currently maintain PCI DSS compliance.

Does MSD Portugal comply with HIPAA ?

According to Rankiteo, MSD Portugal is not compliant with HIPAA regulations.

Does MSD Portugal have ISO 27001 certification ?

According to Rankiteo,MSD Portugal is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does MSD Portugal operate in ?

MSD Portugal operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does MSD Portugal have ?

MSD Portugal employs approximately 118 people worldwide.

Does MSD Portugal own any subsidiaries ?

MSD Portugal presently has no subsidiaries across any sectors.

How many LinkedIn followers does MSD Portugal have ?

MSD Portugal's official LinkedIn profile has approximately 33,120 followers.

Does MSD Portugal have a Crunchbase profile ?

No, MSD Portugal does not have a profile on Crunchbase.

Does MSD Portugal have a LinkedIn profile ?

Yes, MSD Portugal maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/msdportugal.

How many cybersecurity incidents has MSD Portugal experienced ?

As of August 9, 2026, Rankiteo reports that MSD Portugal has experienced 1 cybersecurity incidents.

How many peer or competitor companies does MSD Portugal have ?

MSD Portugal has an estimated 5,727 peer or competitor companies worldwide.

What types of cybersecurity incidents has MSD Portugal faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

MSD Portugal

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

MSD Portugal Vendor Cyber Rating & Cyber Score

msd.pt

Add Your Compliance Badge

Fizemos grandes coisas no passado. Hoje, estamos a fazer grandes coisas para o futuro. Presente em Portugal desde 1970, a MSD revela-se, desde o primeiro momento, fiel aos princípios de inovação e melhoria contínua da saúde e do bem-estar das pessoas. Sendo um dos maiores laboratórios farmacêuticos do mundo e parceiro ativo em todas as questões relacionadas com a área da Saúde, a MSD apresenta soluções inovadoras que contribuem para a preservação e melhoria da vida de milhões de pessoas. Há mais de um século que a MSD tem feito descobertas para resolver alguns dos maiores desafios relativos à saúde e bem-estar das pessoas em todo o mundo.

MSD Portugal A.I CyberSecurity Scoring

Scoring History

MSD Portugal

MSD Portugal CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

MSD Portugal

Breach

9/2025

MSD060270611182...

Loading…

A.I.

MSD Portugal Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for MSD Portugal

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD Portugal in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for MSD Portugal in 2026.

Incident Types MSD Portugal vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD Portugal in 2026.

Incident History - MSD Portugal (X = Date, Y = Severity)

Loading…

SUBSIDIARY

MSD Portugal Subsidiaries

MSD Portugal

Pharmaceutical Manufacturing

Website: http://msd.pt/

Company Size: 118

MSDPharmaceutical Manufacturing

MSD LATAMPharmaceutical Manufacturing

MSD Animal HealthPharmaceutical Manufacturing

MSD GCCPharmaceutical Manufacturing

MSD JordanPharmaceutical Manufacturing

MSD PolskaPharmaceutical Manufacturing

MSD EspañaPharmaceutical Manufacturing

MSD LebanonPharmaceutical Manufacturing

MSD ÖsterreichPharmaceutical Manufacturing

MSD ItaliaPharmaceutical Manufacturing

MSD SverigePharmaceutical Manufacturing

MSD DanmarkPharmaceutical Manufacturing

MSD NorgePharmaceutical Manufacturing

MSD SwitzerlandPharmaceutical Manufacturing

MSD Animal Health UK LtdPharmaceutical Manufacturing

MSD FrancePharmaceutical Manufacturing

MSD EgyptPharmaceutical Manufacturing

MSD FinlandPharmaceutical Manufacturing

MSD SRBIJAPharmaceutical Manufacturing

MSD RomaniaPharmaceutical Manufacturing

MSD NetherlandsPharmaceutical Manufacturing

MSD Australia & New ZealandPharmaceutical Manufacturing

MSD Czech RepublicPharmaceutical Manufacturing

MSD Saúde AnimalVeterinary Services

MSD SlovenskoPharmaceutical Manufacturing

MSD Animal Health Technology LabsTechnology, Information and Internet

MSD MagyarországPharmaceutical Manufacturing

MSD South AfricaPharmaceutical Manufacturing

MSD BelgiumPharmaceutical Manufacturing

MSD TürkiyePharmaceutical Manufacturing

MSD UkrainePharmaceutical Manufacturing

MSD in the UKPharmaceutical Manufacturing

MSD GreecePharmaceutical Manufacturing

MSD DeutschlandPharmaceutical Manufacturing

Loading…

MSD Portugal Similar Companies

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Loading…

NEWS

MSD Portugal CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

May 21, 2024 07:00 AM

14 companies hiring in cybersecurity right now

A round-up of the most intersting companies currently hiring in the cybersecurity sector and information about where to apply.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-71983

SUMMARY

MSI Radix AXE6600 router firmware version v781521 contains a command injection vulnerability in the wps.cgi interface that allows remote attackers to execute arbitrary commands by injecting malicious input through the pin2g, pin5g, or pin6g parameters. Attackers can exploit these unsanitized parameters to execute arbitrary commands on the affected device and obtain root privileges.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-71502

SUMMARY

CTI-Transmute contains a stored cross-site scripting vulnerability caused by insufficient neutralization of Vue template expression delimiters in server-rendered user-controlled data. An unauthenticated attacker can create a public conversion whose name or description contains a malicious Vue expression using the application's configured [[ ... ]] delimiters. User profile names may provide an additional injection vector. Although Jinja HTML escaping is applied, the resulting value is subsequently included in a DOM region compiled by Vue. Vue interprets the attacker-controlled value as a template expression rather than ordinary text. By accessing the JavaScript Function constructor from within the expression, an attacker can execute arbitrary JavaScript in the security context of the CTI-Transmute origin. The application's nonce-based Content Security Policy does not prevent exploitation because the Vue runtime compiler requires the unsafe-eval policy exception. The malicious payload is stored by the application and executed whenever another user opens an affected page, such as the public conversion detail page. The victim may be a normal user or an administrator. Successful exploitation could allow the attacker to: * Access data available to the victim through the application. * Extract API keys, tokens, or other sensitive information exposed to the page. * Perform authenticated actions using the victim's session. * Modify conversions or other application data. * Escalate the impact by targeting an administrator. A demonstrated payload can use [].constructor.constructor(...) to obtain the JavaScript Function constructor and execute arbitrary code. The regression tests also show that a short first-stage payload could retrieve an uncapped conversion description and evaluate a larger second-stage payload. The patch addresses the vulnerability by registering a global Jinja finalize hook that inserts a zero-width Unicode word joiner inside every Vue delimiter found in server-rendered values. This prevents Vue from recognizing the values as template expressions while preserving their visible representation.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: )

cvss4

Base Score: 5.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:A/VC:L/VI:L/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-71958

SUMMARY

D-Link DWR-M961 devices with hardware version C1 and software version 1.1.2_C1_202602110044 contain a buffer overflow vulnerability in the quicksetup.cgi interface. A remote attacker can write overly long strings to the test4, ssid2, and username fields and execute arbitrary commands by crafting a specific payload, or cause the device to crash.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-71957

SUMMARY

D-Link DWR-M961 devices with hardware version C1 and software version 1.1.2_C1_202602110044 contain a buffer overflow vulnerability in the app.cgi interface. A remote attacker can write an overly long string to the netAcc.addlist[].name field and execute arbitrary commands by crafting a specific payload, or cause the device to crash.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-71956

SUMMARY

D-Link DWR-M961 devices with hardware version C1 and software version 1.1.2_C1_202602110044 contain a command injection vulnerability in the app.cgi interface. A remote attacker can inject arbitrary malicious commands into the netDig.ping.dst field, resulting in command execution with root privileges.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…